OakChart

Cardiol Therapeutics Inc

CRDLHealthcare·Drug Manufacturers - Specialty & Generic·Canada·Micro·NASD·Nov 11 • 3:59 PM ET

1.01-0.01 (-0.98%)
2026-11-12 05:38 CET
Market cap
121.87 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-24.69 USD m
Free cash flow, TTM
-17.29 USD m
EPS diluted, TTM
-0.25
P/E
-
Compare

Price

CRDL against its 20, 50 and 200-day averages
2050200beatmiss
1.001.502.002.4M4.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CRDLclose 1.0120-day 1.0950-day 1.46200-day 1.301.0152w high52w low

56.8% under the 52-week high of 2.34 on 9 Sep 2026. 52-week low 0.88 on 1 Dec 2025. Last 15 sessions, 33.3% high to low

Volume 0.39× normal · the line is the 50-bar volume average

Profile

CRDL
52-week range, 9% of the way up
0.882.34

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Employees23
IPOJan 15, 2019
Beta0.98
ATR, 14d0.07
Rel volume0.39
Short float2.22%
Insider own2.93%
Inst own26.51%

Snapshot

6 groups

Valuation

Index-
Market Cap121.87M
Enterprise Value103.57M
Income-24.69M
Sales0.00M
Book/sh0.15
Cash/sh0.15
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees23
IPOJan 15, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B6.91
P/C6.63
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.55
Current Ratio5.55
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.25
EPS next Y-0.22
EPS next Q-0.06
EPS this Y-12.81%
EPS next Y28.72%
EPS next 5Y72.39%
EPS past 3/5Y9.88% 11.60%
Sales past 3/5Y- -
EPS Y/Y TTM28.85%
Sales Y/Y TTM-
EPS Q/Q47.67%
Sales Q/Q-
EarningsAug 13 BMO
EPS/Sales Surpr.48.49% -

Ownership

Insider Own2.93%
Insider Trans0.00%
Inst Own26.51%
Inst Trans3.00%
ROA-139.86%
ROE-192.95%
ROIC-145.37%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-7.05%
SMA50-31.00%
SMA200-22.49%
Trades-

Technical

Shs Outstand120.66M
Shs Float117.12M
Short Float2.22%
Short Ratio1.95
Short Interest2.60M
52W High2.34 -56.84%
52W Low0.88 14.77%
Volatility7.70% 5.69%
ATR (14)0.07
RSI (14)33.36
Beta0.98
Rel Volume0.39
Avg Volume1.33M
Volume514,224

Performance

Perf Week0.00%
Perf Month-15.83%
Perf Quarter-40.94%
Perf Half Y-25.74%
Perf YTD5.89%
Perf Year-2.88%
Perf 3Y32.91%
Perf 5Y-59.27%
Perf 10Y-
Recom1.00
Target Price7.89
Prev Close1.02
Price1.01
Change %-0.98%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Aug 26, 2026InitiatedRB. Riley SecuritiesBuy$11+989.1%
Jun 02, 2025InitiatedHH.C. WainwrightBuy$9+791.1%
Jan 28, 2025InitiatedRRodman & RenshawBuy$7+593.1%
Jun 26, 2024InitiatedRROTH MKMBuy$10+890.1%
Apr 22, 2024InitiatedHH.C. WainwrightBuy$9+791.1%

Peers

Mkt cap
TickerCompanyMkt cap
KNSAKiniksa Pharmaceuticals International Plc7.52B
CPIXCumberland Pharmaceuticals Inc91.70M
IXHLIncannex Healthcare Inc24.77M
TENXTenax Therapeutics Inc76.96M
MISTMilestone Pharmaceuticals Inc82.44M
CYTKCytokinetics Inc8.15B
LXRXLexicon Pharmaceuticals Inc832.59M
MNKDMannkind Corp1.35B
MTRIMentari Therapeutics Inc8.57M
JAZZJazz Pharmaceuticals plc15.93B

Held by

AUM
TickerCompanyAUM
GWXState Street SPDR S&P International Small Cap ETFAUM: 906.57M

News

latest 14 of 200
  • Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC (PR Newswire)
  • Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx's Efficacy (PR Newswire) -6.35%
  • Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds (PR Newswire)
  • Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission (PR Newswire) -13.35%
  • Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
  • Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference (PR Newswire)
  • Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association (PR Newswire) +8.49%
  • Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit (PR Newswire)
  • Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders (PR Newswire)
  • Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT (PR Newswire)
  • Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ (PR Newswire)
  • Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association (PR Newswire)
  • Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program (PR Newswire)
  • Upcoming Meeting Dates - April 20, 2026 (Newsfile)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.036-0.070-0.0360.000.003
2026Q12026-05-11-0.073-0.065-0.0720.000.003
2025Q42026-03-31-0.050-0.083-0.0520.000.003
2025Q32025-11-18-0.086-0.072-0.0850.000.003
2025Q22025-08-19-0.072-0.080-0.0730.000.003
2025Q12025-05-16-0.072-0.083-0.0700.000.002
2024Q42025-03-27-0.081-0.089-0.0720.000.003
2024Q32024-11-12-0.140-0.092-0.1340.000.003
2024Q22024-08-15-0.073-0.103-0.0700.000.003
2024Q12024-05-14-0.103-0.088-0.1010.000.002
2023Q42024-04-01-0.104-0.089-0.0860.000.001
2023Q32023-11-15-0.066-0.087-0.0690.000.001
2023Q22023-08-10-0.089-0.093-0.0870.000.002
2023Q12023-05-23-0.082-0.082-0.0820.000.002
2022Q42023-03-28-0.088-0.060-0.0860.000.001
2022Q32023-01-31-0.097--0.0980.00-2

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.405-0.396-0.3990.000.00
2020FY-0.549-0.327-0.5150.000.00
2021FY-0.581-0.400-0.5840.060.45
2022FY-0.360-0.336-0.3800.000.00
2023FY-0.324-0.322-0.3230.000.00
2024FY-0.403-0.417-0.3740.000.00
2025FY-0.280-0.336-0.2810.000.00
2026FY--0.315--0.00
2027FY--0.225--1.75
2028FY--0.006--44.55
2029FY-0.238--111.79
2030FY-0.653--212.43

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-192000.000.000.00
2026Q3S2026-08-133000.000.000.00
2026Q3S2026-05-113000.000.000.00
2026Q3S2026-04-013000.000.000.00
2026Q3S2025-11-132000.000.000.00
2026Q3S2025-11-112000.000.000.00
2026Q3S2025-11-102000.000.000.00
2026Q3S2025-11-092000.000.000.00
2026Q3S2025-11-082000.000.000.00
2026Q3S2025-11-072000.000.000.00
2026Q3S2025-11-062000.000.000.00
2026Q3S2025-11-052000.000.000.00
2026Q3S2025-11-042000.000.000.00
2026Q3S2025-11-032000.000.000.00

Estimate history

EPS, annual-0.055-0.798-0.399-0.515-0.584-0.38-0.323-0.374-0.278-0.2476
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.07-0.134-0.072-0.07-0.073-0.085-0.052-0.072-0.038
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000.06300000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual23.16122.72725.87832.8661.92364.04365.35282.609100.257115.885
Period201720182019202020212022202320242025MRQ
Shares, quarterly69.32370.19782.60982.60982.67587.456100.257111.872115.885
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.060.000.000.00
Cost of Goods Sold Incl. D&A0.060.070.270.180.170.180.170.110.07
Gross Profit-0.06-0.07-0.27-0.18-0.17-0.11-0.17-0.11-0.07
Selling, General and Administrative Excl. Other25.9024.4929.1321.8831.5830.7315.2510.535.40
Research and Development11.3610.0310.2310.5414.578.677.842.661.18
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-25.96-24.56-29.40-22.07-31.75-30.84-15.43-10.65-5.47
Interest Expense-------0.000.51
Unusual Expense-0.40-0.68-0.17-0.13-4.790.000.000.006.39
Net Income Before Taxes-24.69-24.20-26.77-20.84-23.76-25.24-15.39-10.31-12.26
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-24.69-24.20-26.77-20.84-23.76-25.24-15.39-10.31-12.26
Net Income From Continuing Operations-24.69-24.20-26.77-20.84-23.76-25.24-15.39-10.31-12.26
Net Income-24.69-24.20-26.77-20.84-23.76-25.24-15.39-10.31-12.26
EPS (Recurring)-0.22-0.28-0.38-0.32-0.43-0.58-0.52-0.40-0.51
EPS (Basic, Before Extraordinaries)-0.25-0.28-0.37-0.32-0.38-0.58-0.52-0.40-0.80
EPS (Diluted)-0.25-0.28-0.37-0.32-0.38-0.58-0.52-0.40-0.80
EBITDA-25.90-24.49-29.13-21.88-31.58-30.66-15.25-10.53-5.40
Non-Operating Income (Expense)0.87-0.332.451.093.205.600.040.330.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.147.6610.423.085.917.732.062.461.28
Price To Sales Ratio-----1,269.15---
Gross Margin------179.86---
Operating Margin------49,092.25---
Net Margin------40,170.71---
Shares Outstanding115.88100.2682.6165.3564.0461.9232.8625.8822.73
Market Capitalization121.87121.87104.4554.9031.9747.8956.4391.5191.09

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.020.020.020.020.020.030.15
Gross Profit-0.01-0.02-0.02-0.02-0.02-0.02-0.03-0.15
Selling, General and Administrative Excl. Other5.737.065.747.375.525.867.1110.22
Research and Development2.313.611.973.481.972.623.022.75
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.73-7.08-5.76-7.39-5.54-5.87-7.14-10.37
Unusual Expense-0.831.12-0.680.000.000.00-0.00-0.99
Net Income Before Taxes-4.39-7.89-5.17-7.24-6.03-5.78-5.85-9.33
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.39-7.89-5.17-7.24-6.03-5.78-5.85-9.33
Net Income From Continuing Operations-4.39-7.89-5.17-7.24-6.03-5.78-5.85-9.33
Net Income-4.39-7.89-5.17-7.24-6.03-5.78-5.85-9.33
EPS (Recurring)-0.04-0.07-0.06-0.09-0.07-0.07-0.07-0.14
EPS (Basic, Before Extraordinaries)-0.04-0.07-0.05-0.09-0.07-0.07-0.07-0.13
EPS (Diluted)-0.04-0.07-0.05-0.09-0.07-0.07-0.07-0.13
EBITDA-5.73-7.06-5.74-7.37-5.52-5.86-7.11-10.22
Non-Operating Income (Expense)0.510.30-0.100.16-0.490.101.290.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.502.572.162.901.830.802.256.17
Shares Outstanding115.88111.87100.2687.4682.6782.6182.6170.20
Market Capitalization121.87150.7795.3889.59112.4079.14104.45138.37

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments15.6221.2626.4943.8966.4211.015.3612.251.88
Short Term Receivables0.170.250.210.350.320.170.720.340.08
Inventories0.000.000.000.000.000.010.860.000.00
Other Current Assets1.360.510.711.102.240.544.145.000.02
Total Current Assets17.1522.0227.4245.3468.9911.7311.0817.591.98
Net Property, Plant & Equipment0.090.140.260.220.280.380.450.020.02
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.160.220.300.360.420.460.57
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets17.2322.1627.8345.7869.5712.4811.9618.072.57
Short Term Debt Incl. Current Port. of LT Debt0.030.020.010.040.040.040.040.000.00
Accounts Payable0.000.000.006.163.320.000.000.000.00
Other Current Liabilities4.104.856.281.045.801.940.491.570.14
Total Current Liabilities4.134.876.297.249.161.980.531.570.14
Long Term Debt0.060.090.120.020.060.080.110.200.11
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.04
Total Liabilities4.194.966.417.259.212.060.641.760.29
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity13.0417.1921.4238.5360.3610.4211.3116.312.28
Total Shareholders Equity13.0417.1921.4238.5360.3610.4211.3116.312.28
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity13.0417.1921.4238.5360.3610.4211.3116.312.28
Total Liabilities & Stockholders Equity17.2322.1627.8345.7869.5712.4811.9618.072.57
Book Value Per Share0.130.210.330.600.970.320.440.720.10
Tangible Book Value Per Share0.130.210.330.600.970.310.420.700.07
Full-Time Employees2322222219141912-
Price to Book Ratio6.9111.642.120.761.906.888.097.25-
Return on Assets-122.90-107.12-56.62-41.20-61.52-125.98-68.69-118.80-
Return on Equity-160.09-138.66-69.53-48.06-71.31-141.63-74.67-131.95-
Return on Invested Capital-184.67-154.92-96.74-61.64-41.77-146.58-90.28-74.29-53.54
Quick Ratio4.164.524.366.277.535.9319.1911.2214.06
Current Ratio4.164.524.366.277.535.9420.8111.2214.06

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-24.44-24.20-26.77-20.84-23.76-25.24-15.39-10.31-12.26
Depreciation0.060.070.270.180.170.180.170.110.07
Other Funds (Non Cash)7.387.588.892.40-1.736.212.172.847.80
Funds from Operations-17.00-16.55-17.61-18.25-25.32-18.85-13.05-7.36-4.39
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.25-0.52-0.68-0.404.420.066.20-1.22-4.01
Cash from Operating Activities-17.25-17.07-18.29-18.66-20.91-18.78-6.85-8.58-8.40
Capital Expenditures-0.04-0.02-0.02-0.05-0.06-0.01-0.03-0.32-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.04-0.02-0.02-0.05-0.06-0.01-0.03-0.32-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock22.7911.1613.780.000.0074.5712.191.5410.19
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock22.7911.1613.780.000.0074.5712.191.5410.19
Proceedsfrom Stock Options20.9911.1413.650.000.0062.8912.051.2610.19
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.009.31
Change in Long Term Debt0.000.000.000.000.000.000.000.009.31
Issuance of Long Term Debt0.000.000.000.000.000.000.000.009.31
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities22.7511.1213.75-0.04-0.0474.5312.151.5319.51
Exchange Rate Effect0.28-0.591.380.562.24----
Net Change in Cash5.74-6.56-3.18-18.18-18.7655.735.27-7.3711.09
Free Cash Flow-17.29-17.09-18.31-18.70-20.97-18.79-6.88-8.90-8.42
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments18.3819.8315.628.3513.3316.18
Short Term Receivables0.220.240.170.140.210.24
Inventories0.000.000.000.000.000.00
Other Current Assets2.002.331.360.710.951.13
Total Current Assets20.6022.4117.159.2014.4917.56
Net Property, Plant & Equipment0.090.100.090.100.120.13
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets20.6922.5017.239.3114.6117.69
Short Term Debt Incl. Current Port. of LT Debt0.030.030.030.030.030.02
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities3.685.084.102.345.855.36
Total Current Liabilities3.715.114.132.365.885.39
Long Term Debt0.050.050.060.070.080.08
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.765.164.192.435.965.47
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity16.9417.3413.046.878.6512.22
Total Shareholders Equity16.9417.3413.046.878.6512.22
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity16.9417.3413.046.878.6512.22
Total Liabilities & Stockholders Equity20.6922.5017.239.3114.6117.69
Book Value Per Share0.150.160.130.080.100.15
Tangible Book Value Per Share0.150.160.130.080.100.15
Full-Time Employees--23---
Price to Book Ratio6.9110.3812.1410.229.194.66
Return on Assets-139.86-131.02-122.97-223.52-159.51-126.69
Return on Equity-192.95-178.11-160.19-341.16-271.53-190.61
Return on Invested Capital-25.87-45.33-39.47-104.24-69.09-46.96
Quick Ratio5.554.394.163.892.463.26
Current Ratio5.554.394.163.892.463.26

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.32-7.89-4.93-7.30-6.24-5.78
Depreciation0.010.020.020.020.020.02
Other Funds (Non Cash)0.642.301.792.662.280.88
Funds from Operations-3.67-5.57-3.13-4.63-3.95-4.88
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.560.09-0.45-0.450.48-0.11
Cash from Operating Activities-3.11-5.48-3.58-5.08-3.47-4.99
Capital Expenditures-0.00-0.03-0.00-0.00-0.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.00-0.03-0.00-0.00-0.00-0.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.719.9211.160.000.020.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.719.9211.160.000.020.00
Proceedsfrom Stock Options-0.099.9211.160.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.709.9111.15-0.010.01-0.01
Exchange Rate Effect0.220.16-0.370.27-0.41-0.08
Net Change in Cash-1.194.567.19-4.82-3.86-5.08
Free Cash Flow-3.11-5.52-3.58-5.08-3.47-4.99

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.22%2.6M117.1M1.38M
2026-10-152.43%2.8M117.1M1.44M
2026-09-302.63%3.1M117.0M1.21M
2026-09-152.92%3.3M113.3M1.11M
2026-08-312.58%2.9M113.3M926.42K
2026-08-142.04%2.3M113.4M674.69K
2026-07-312.00%2.3M112.5M562.52K
2026-07-151.98%2.2M111.9M532.64K
2026-06-301.98%2.2M111.8M532.19K
2026-06-151.87%2.1M111.8M678.48K
2026-05-291.77%1.9M108.5M675.89K
2026-05-151.81%2.0M108.5M680.83K
2026-04-301.81%2.0M108.5M675.92K
2026-04-151.83%2.0M108.5M593.46K
2026-03-311.85%2.0M107.1M531.98K
2026-03-131.96%2.1M106.9M339.12K
2026-02-272.10%2.2M106.9M438.36K
2026-02-131.95%2.1M106.9M452.05K
2026-01-302.12%2.0M95.7M448.65K
2026-01-152.03%1.9M95.7M548.15K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.101.100.540.0002.000.000.907-0.0070.000
call1.000.001.001.000.00029.000.000.681-0.0190.001
call1.500.000.550.058.5804.000.000.645-0.0280.001
call2.000.000.050.053.79410.000.000.195-0.0090.000
call2.500.000.050.054.24910.000.000.174-0.0090.000
call5.000.000.950.006.1250.000.000.140-0.0120.000
call7.500.001.000.007.0970.000.000.129-0.0130.000
put0.500.000.050.004.6940.000.00-0.095-0.0070.000
put1.000.000.350.105.99019.000.00-0.165-0.0270.000
put1.500.101.100.0011.0150.000.00-0.258-0.0290.001
put2.000.501.500.0011.6960.000.00-0.805-0.0090.000
put2.501.052.050.0012.4910.000.00-0.825-0.0100.000
put5.003.504.500.0014.0160.000.00-0.860-0.0110.000
put7.506.107.100.0015.8610.000.00-0.871-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-11-03SUPPLVoluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuersSEC
2026-09-23SCHEDULE 13G/ASEC
2026-09-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-23SEC
2026-09-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-16SEC
2026-09-16SUPPLVoluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuersSEC
2026-09-16F-10/ASEC
2026-09-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-09-10F-XFor appointment of agent for service of process by issuers registering securities (if filed on Form F-8, F-9, F-10 or F-80, or registering securities or filing periodic reports on Form 40-F, or by any person filing certain tender offer documents, or by anSEC
2026-09-10F-10Registration statement for securities of certain Canadian issuers under the Securities Act of 1933SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-05SEC
2026-07-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-14SEC
2026-07-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-09SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-23SEC
2026-05-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-25SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-14SEC
2026-05-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-05-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-07SEC
2026-04-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-28SEC
2026-04-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-14SEC
2026-04-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-10SEC
2026-04-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MMCAP International Inc. SPC13.53%
Tejara Capital Ltd6.15%
Ikarian Capital, LLC2.88%
BOOTHBAY FUND MANAGEMENT, LLC0.85%
CITADEL ADVISORS LLC0.69%
RENAISSANCE TECHNOLOGIES LLC0.67%
TWO SIGMA INVESTMENTS, LP0.65%
MORGAN STANLEY0.31%
GOLDMAN SACHS GROUP INC0.29%
INTEGRITY ALLIANCE, LLC.0.26%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.02%

OakChart. CRDL. Cached 15 minutes.

Some panels did not load: insider.